Crossmark

Effects of combinations of gapmer antisense oligonucleotides on the target reduction

Crossref DOI link: https://doi.org/10.1007/s11033-022-08224-0

Published Online: 2023-02-14

Published Print: 2023-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yanagidaira, Mitsugu https://orcid.org/0000-0002-4694-6227
Yoshioka, Kotaro https://orcid.org/0000-0001-7094-9017
Nagata, Tetsuya https://orcid.org/0000-0003-4111-2693
Nakao, Shoichi

Miyata, Kenichi

Yokota, Takanori https://orcid.org/0000-0002-6490-3263
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development (JP21wm0525032)

JST FOREST Program (JPMJFR216H)

JSPS KAKENHI Grant-in-Aid for Challenging Research (JP20K21882)

JSPS KAKENHI Scientific Research (JP22H02979)

Takeda Science Foundation (Takeda Science Foundation)

Basic Science and Platform Technology 366 Programs for Innovative Biological Medicine (18am0301003h0005)

Advanced Biological 367 Medicine (20am0401006h0002)
License Information

Text and Data Mining valid from 2023-02-14

Version of Record valid from 2023-02-14
More Information

Article History

Received: 3 October 2022

Accepted: 20 December 2022

First Online: 14 February 2023

Declarations

:

: T.Y. collaborates with Takeda Pharmaceutical Company, Ltd., Daiichi Sankyo Company, Ltd., Rena Therapeutics, Inc., and serves as the academic adviser for Rena Therapeutics, Inc., and Braizon Therapeutics, Inc. K. M. is and S.N. was paid employees of Takeda Pharmaceutical Company Limited. All other authors declare no competing financial interests. All authors read and approved the final manuscript.

: This manuscript does not contain any studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below